Yariv Houvras

4.4k total citations
46 papers, 1.5k citations indexed

About

Yariv Houvras is a scholar working on Molecular Biology, Hematology and Cell Biology. According to data from OpenAlex, Yariv Houvras has authored 46 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 12 papers in Hematology and 11 papers in Cell Biology. Recurrent topics in Yariv Houvras's work include Multiple Myeloma Research and Treatments (11 papers), Zebrafish Biomedical Research Applications (8 papers) and Protein Degradation and Inhibitors (7 papers). Yariv Houvras is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Zebrafish Biomedical Research Applications (8 papers) and Protein Degradation and Inhibitors (7 papers). Yariv Houvras collaborates with scholars based in United States, Belgium and Italy. Yariv Houvras's co-authors include Jonathan D. Licht, Barbara L. Weber, Hongxiang Zhang, Yi‐Xin Zeng, Kumaravel Somasundaram, Gen Sheng Wu, Hongbing Zhang, Yi Peng, Wafik S. El‐Deiry and Craig J. Ceol and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Yariv Houvras

44 papers receiving 1.5k citations

Peers

Countries citing papers authored by Yariv Houvras

Since Specialization

Citations

This map shows the geographic impact of Yariv Houvras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yariv Houvras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yariv Houvras more than expected).

Fields of papers citing papers by Yariv Houvras

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yariv Houvras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yariv Houvras. The network helps show where Yariv Houvras may publish in the future.

Co-authorship network of co-authors of Yariv Houvras

This figure shows the co-authorship network connecting the top 25 collaborators of Yariv Houvras. A scholar is included among the top collaborators of Yariv Houvras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yariv Houvras. Yariv Houvras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC) 2025 ·Annals of Oncology ·(unknown), (unknown), Elena Ioana Braicu, Shiraj Sen, Valentina Boni, Rebecca Kristeleit, (unknown), Sebastian Ochsenreither, Debra L. Richardson, (unknown), (unknown), Juergen Wolf, (unknown), Barry D. Hock, Yariv Houvras, Inês Vasconcelos, Günter Fingerle‐Rowson, Toon Van Gorp	0
2	Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·Sundar Jagannath, Hans C. Lee, Joshua Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng‐Yi Zhou, (unknown), Mirko Fillbrunn, (unknown), (unknown), Qiufei Ma, (unknown), Yingxin Xu, (unknown), James Harnett, Tito Roccia, Glenn S. Kroog, Karen Rodriguez-Lorenc, Yariv Houvras, Naresh Bumma	1
3	P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jeffrey A. Zonder, Hans C. Lee, Joshua Richter, Naresh Bumma, Zheng‐Yi Zhou, (unknown), Mirko Fillbrunn, (unknown), (unknown), (unknown), Qiufei Ma, (unknown), Yingxin Xu, (unknown), James Harnett, Tito Roccia, Glenn S. Kroog, Karen Rodriguez Lorenc, Yariv Houvras, Sundar Jagannath	1
4	P-029 Pharmacokinetics (PK) and Immunogenicity of Linvoseltamab in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in LINKER-MM1 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Anasuya Hazra, (unknown), (unknown), Yariv Houvras, Glenn S. Kroog, Karen Rodriguez Lorenc, A. Thomas DiCioccio, John Davis	1
5	Depletion of tet2 results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome 2023 ·PubMed ·Yaseswini Neelamraju, (unknown), Sagar Chhangawala, (unknown), Shuning He, Changbin Jing, (unknown), (unknown), Caroline Sheridan, Yariv Houvras, Ari Melnick, A. Thomas Look, Francine E. Garrett-Bakelman	1
6	RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype 2022 ·Annals of Surgical Oncology ·Timothy M. Ullmann, (unknown), Yeon Joo Lee, Shaham Beg, Juan Miguel Mosquera, Olivier Elemento, Thomas J. Fahey, Theresa Scognamiglio, Yariv Houvras	14
7	Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms 2022 ·Frontiers in Cell and Developmental Biology ·(unknown), (unknown), Hao Shen, Ashley S. Doane, Alexendar R. Perez, Akanksha Verma, (unknown), (unknown), (unknown), Caitlin Bourque, Jun Yao, Renuka Raman, Wendy Béguelin, Jonathan H. Zippin, Olivier Elemento, Ari Melnick, Yariv Houvras	5
8	PPP6C, a serine-threonine phosphatase, regulates melanocyte differentiation and contributes to melanoma tumorigenesis through modulation of MITF activity 2022 ·Scientific Reports ·(unknown), Renuka Raman, Yariv Houvras	6
9	Synthetic CRISPR/Cas9 reagents facilitate genome editing and homology directed repair 2020 ·Nucleic Acids Research ·(unknown), (unknown), Caitlin Gribbin, Paul J. Wrighton, (unknown), (unknown), (unknown), (unknown), Arkadi Shwartz, (unknown), (unknown), (unknown), Sean C. McConnell, Jill L. O. de Jong, Wolfram Goessling, Yariv Houvras	34
10	Fetal alcohol spectrum disorder predisposes to metabolic abnormalities in adulthood 2020 ·Journal of Clinical Investigation ·Olivia Weeks, Gabriel D. Bossé, Isaac M. Oderberg, Sebastian Akle, Yariv Houvras, Paul J. Wrighton, Kyle A. LaBella, (unknown), Sahar Tavakoli, Isaac Adatto, (unknown), Daan J. Kloosterman, (unknown), Michael E. Charness, Randall T. Peterson, Matthew L. Steinhauser, Pouneh K. Fazeli, Wolfram Goessling	36
11	Estrogen Activation of G-Protein–Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes 2019 ·Gastroenterology ·(unknown), Arkadi Shwartz, Kimberley Evason, Andrew G. Cox, Kyle A. LaBella, Arnout Schepers, Song Yang, (unknown), Yariv Houvras, Liliana Mâncio-Silva, (unknown), Daniel A. Gorelick, David E. Cohen, Leonard I. Zon, Sangeeta N. Bhatia, Trista E. North, Wolfram Goessling	82
12	Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression 2017 ·eLife ·Viviana Anelli, Jacques A. Villefranc, Sagar Chhangawala, (unknown), (unknown), (unknown), Akanksha Verma, Rohan Bareja, Zhengming Chen, Theresa Scognamiglio, Olivier Elemento, Yariv Houvras	47
13	Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma 2017 ·Journal of Clinical Investigation ·(unknown), Rajesh Vyas, (unknown), Karen Dresser, Sharvari Gujja, Sanchita Bhatnagar, Sagar Chhangawala, Camilla Borges Ferreira Gomes, Hualin Simon Xi, Christine G. Lian, Yariv Houvras, Yvonne J. K. Edwards, April Deng, Michael R. Green, Craig J. Ceol	40
14	Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish 2016 ·Nature Communications ·Qin Tang, John C. Moore, Myron S. Ignatius, Inês M. Tenente, Madeline N. Hayes, Elaine G. Garcia, (unknown), Caitlin Bourque, Shuning He, Jessica S. Blackburn, A. Thomas Look, Yariv Houvras, David M. Langenau	70
15	SPOP mutation leads to genomic instability in prostate cancer 2015 ·eLife ·Gunther Boysen, Christopher E. Barbieri, Davide Prandi, Mirjam Blattner, Sung‐Suk Chae, (unknown), Srilakshmi Nataraj, Dennis Huang, Clarisse Marotz, Limei Xu, Julie Huang, Paola Lecca, Sagar Chhangawala, Deli Liu, Pengbo Zhou, Andrea Sboner, Johann S. de Bono, Francesca Demichelis, Yariv Houvras, Mark A. Rubin	132
16	Optimized cell transplantation using adult rag2 mutant zebrafish 2014 ·Nature Methods ·Qin Tang, Nouran S. Abdelfattah, Jessica S. Blackburn, John C. Moore, Sarah Martinez, Finola E. Moore, Riadh Lobbardi, Inês M. Tenente, Myron S. Ignatius, Jason N. Berman, Robert Liwski, Yariv Houvras, David M. Langenau	115
17	Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial 2013 ·The Journal of Clinical Endocrinology & Metabolism ·Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras, Michael E. Menefee, Keith C. Bible, Manisha H. Shah, Ann W. Gramza, Joshua Klopper, Laura A. Marlow, Michael G. Heckman, Reinhard von Roemeling	93
18	Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model 2012 ·Journal of Visualized Experiments ·(unknown), Yariv Houvras, Craig J. Ceol	22
19	Melanoma Biology and the Promise of Zebrafish 2008 ·Zebrafish ·Craig J. Ceol, Yariv Houvras, Richard M. White, Leonard I. Zon	34
20	The Effect of a Depth Gradient on the Mating Behavior, Oviposition Site Preference, and Embryo Production in the Zebrafish, Danio rerio 2008 ·Zebrafish ·Anna K. Sessa, Richard White, Yariv Houvras, Christopher J. Burke, Emily K. Pugach, Barry W. Baker, (unknown), A. Thomas Look, Leonard I. Zon	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact